When Dr. Yochi Hagay and Dr. Zaki Rakib met in Israel in 2007, they realized that they can leverage their complementary skill sets to execute on the common vision of leveraging nature for improving human’s wellness and health. With Dr. Hagay’s vast 25 years of pharmaceutical experience and Dr. Rakib’s proven track record of creating successful companies, they embarked on the BioHarvest journey that brought to the world the breakthrough Biofarming technology. This plant cell growth technology avails abundantly to human beings the active secondary metabolites needed to support their health and improves their wellness. It does so without the need to grow the plant itself.
They founded BioHarvest in the science park of the city of Rehovot, which is the hub of biotech innovation in Israel. They hired great talents in plant biology who until this day are working diligently to further advance the Biofarming technology and adapt it to new verticals.
After years of R&D, BioHarvest became the first and only company that grows cells of plants at industrial scale in liquid bioreactors in order to produce the secondary metabolites.
The first product (Vinia) which is based on red grape contains a rich complex of polyphenols. Vinia was clinically proven to bring significant cardiovascular benefits. Each and every claim made by BioHarvest is supported by clinical trials which results have been published in peer reviewed scientific journals. The company built a 2tons/year small size factory that not only proved the industrial feasibility of Biofarming but also allowed in 2017 to start generating revenue from sales of Vinia in Israel. Separately in 2019, the company also started applying the Biofarming technology on Cannabis plants aiming at producing the cannabinoids without the need to grow the Cannabis plant itself. BioHarvest plans to avail its Cannabis products in 2022.
In June of 2020, Mr. Ilan Sobel joined the company as the CEO. Ilan has immediately begun transforming BioHarvest into a fully operationally functional company and added the disciplines of manufacturing, marketing and sales to its existing powerful R&D capabilities. Mr. Sobel has secured the expansion of the manufacturing capacity to a new 20 tons/year facility which will be completed in Q3/2021.